Status:
COMPLETED
Safety and Efficacy of Lorbrena
Lead Sponsor:
Pfizer
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
Brief Summary
To investigate the following matters under post-marketing use of Lorbrena in patients who received this drug 1. Factors affecting the onset of central nervous system disorder 2. Effect of Lorbrena in...
Eligibility Criteria
Inclusion
- All administered patients
Exclusion
- Nothing
Key Trial Info
Start Date :
January 21 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 30 2025
Estimated Enrollment :
1290 Patients enrolled
Trial Details
Trial ID
NCT03844464
Start Date
January 21 2019
End Date
July 30 2025
Last Update
September 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
3-22-7, Yoyogi, Shibuya-ku
Tokyo, Japan, 151-8589